Synergetics USA to Be Acquired by Valeant Pharmaceuticals
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/3/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
- Analysis-Excommunications show a Pope Leo unafraid of making firm decisions
- Canaccord Starts Infleqtion, Inc (INFQ) at Buy
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Jersey Mike's Subs files for IPO on NYSE under ticker JMKE
- Meta CEO Mark Zuckerberg Says In Internal Town Hall That Ai Agent Development Over The Last Four Months Hasn't 'accelerated In The Way We Expected' - Reuters
Stephens Downgrades Synergetics USA (SURG) to Equal Weight
September 3, 2015 8:27 AM EDTStephens downgraded Synergetics USA (NASDAQ: SURG) from Overweight to Equal Weight.
For an analyst ratings summary and ratings history on Synergetics USA click here. For more ratings news on Synergetics USA click here.
Shares of Synergetics USA closed at $6.58 yesterday.
... MoreBMO Capital Remains Bullish on Valeant Pharma (VRX) Following Announced Acquisition of Synergetics USA (SURG)
September 2, 2015 10:23 AM EDTBMO Capital reiterated an Outperform rating and $285.00 price target on Valeant Pharmaceuticals (NYSE: VRX) following the company's announced agreement to buy Synergetics USA (NASDAQ: SURG). Analyst Alex Arfaei said that although this is a small... More
Valeant Pharma (VRX) to Acquire Synergetics USA (SURG) for $6.50/Share + Milestones
September 2, 2015 8:02 AM EDTSynergetics USA, Inc. (NASDAQ: SURG) and Valeant Pharmaceuticals International ("Valeant"), a wholly-owned subsidiary of Valeant Pharmaceuticals International, Inc. (NYSE: VRX), announced that they have entered into a definitive agreement under which Valeant will acquire Synergetics for $6.50 per share in cash. In addition to the upfront cash payment, Synergetics stockholders will receive additional cash payments of up to $1.00 per share if specified sales milestones are achieved following the closing. The transaction is expected to close in the fourth quarter of 2015 and is subject to customary closing conditions and regulatory approvals.
The... More
